ClinicalTrials.gg
CompletedNCT01392768MozartUpdated Oct 31, 2016

Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization

A Phase 3 interventional study of Levetiracetam and Placebo in Epilepsy and Partial Seizures, sponsored by Ache Laboratorios Farmaceuticos S.A.. Completed. Open to participants aged 4 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-10-31.

Sponsored by Ache Laboratorios Farmaceuticos S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
4 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
24th of 60
126 · median 94
Started
2013
with 2 others
Phase 3
28 of 60
2 open now
Registered
41st of 60
by date
Lead sponsor
1 of 60
Ache Laboratorios Farmaceuticos S.A.

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 24th largest by enrollment, is one of 3 that started in 2013, is one of 28 in phase 3, and was the 41st registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.

03

Conditions studied

  • Epilepsy
  • Partial Seizures

Keywords

  • Epilepsy
  • Partial
  • Seizures
  • Adjunctive
04

Who can participate

Ages eligible
4 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients of both sexes, aged between 04 and 65 years, remaining the feasibility of a legal guardian in accordance with need, able to understand and provide written and able to allow compliance at the treatment and the requirements of the protocol;
  • Patient´s weight ≥ 20kg;
  • Consistent diagnosis of focal epilepsy, with or without secondary generalization;
  • Patient with onset of seizures for at least 02 years preceding the screening visit;
  • Presence at least 12 partial seizures during the 03 months preceding the screening visit (04 seizures per month);

    • Only seizures that generate motor manifestation will be recorded in this study.
  • Absence of brain injury progressive or expansive, previously documented by CT scan, MRI or other imaging test applicable (in the last 05 years;
  • Patient with electroencephalogram performed up to 02 years before this visit;
  • Subject with stable regimen (minimum of 01 month) from one to three antiepileptic drugs.

    • Vagus nerve stimulation for 04 weeks prior to V1, or use of benzodiazepines for more than 07 consecutive days will be considered as concomitant epileptic drugs)

Exclusion criteria

Exclusion Criteria:

  • Patients with:

    • Seizures of non epileptic origin;
    • Pseudoseizures;
    • Seizures occurring in clustered patterns (03 or more seizures in 30 minutes), in the 03 months preceding the screening visit (V1);
    • History of status epilepticus while taking antiepileptic drugs during the 03 months that preceding the screening visit (V1).
  • Epileptic syndromes that occurs with cognitive deficits or secondary epilepsy evolving from some brain disease;
  • History of schizophrenia or suicide attempt;
  • Patients with psychiatric ill ongoing;
  • Presence of severe mental retardation of any etiology;
  • Previous exposure to levetiracetam;
  • Women of childbearing age who had tested positive for pregnancy, or who do not use acceptable method, or do not agree to practice reliable contraception during the study;
  • Woman in pregnancy or lactation period;
  • Diagnosis of renal or hepatic failure;
  • Patients with genetic syndromes;
  • Patient that is taking any prohibited medication (Item 9.3);
  • Participation in last one year of clinical protocols, unless it can be direct benefit to subject;
  • Relatives of sponsor´s or study site´s employee;
  • Current evidence of diseases: hematopoietic, gastrointestinal, cardiovascular, hepatic, renal, neurological, endocrine, psychiatric, , pulmonary, or another disease that block the subject participation;
  • Any finding of clinical observation (anamnesis and physical exam) laboratory abnormality (e.g., blood glucose, blood count), disease (for example, liver, cardiovascular system, lung) or therapy that, in opinion of the investigator, may endanger the subject or interfere with the endpoints of study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Drug: Levetiracetam

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)

  • DrugPlacebo

    Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam

06

What researchers measure

Primary outcomes

  1. Partial onset seizure frequency per week.

    Collection of seizure count throughout the whole study

    Time frame: From baseline to week 24

Secondary outcomes

  1. Safety descriptive about occurence of adverse events, evaluation of results of clinical/physical examination and ECG and laboratory tests results.

    Collection of safety data throughout the whole study period

    Time frame: From baseline to week 30

  2. Proportions of response between the groups of treatment. (Responders defined as number of patients with at least 50% reduction in the number of weekly partial seizures)

    Comparative between baseline and treatment periods

    Time frame: From baseline to week 24

  3. Percentage reduction from baseline in partial seizure frequency of days a week.

    Comparative between baseline and treatment periods

    Time frame: From baseline to week 24

  4. Proportion of response between the groups of treatment. (Responders defined as number of subjects with at least 50% reduction in the number of days per week with partial seizures)

    Comparative between baseline and treatment periods

    Time frame: From baseline to week 24

  5. Proportion between the groups of treatment without any kind of seizures. (seizure free)

    During the evaluation period of treatment, without the titration period

    Time frame: 12 weeks after the titration period (period with stable regimen of the drug)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Jul 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2011
First posted
Jul 13, 2011
Start
Jan 2013
Primary completionActual
Jul 2015
CompletionActual
Aug 2015
Last update
Oct 31, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01392768
Responsible party
Sponsor
First posted
Jul 13, 2011
Start date
Jan 2013
Primary completion
Jul 2015
Completion
Aug 2015
Last update
Oct 31, 2016

Study contacts

Elza M Yacubian
principal investigator · Federal University of São Paulo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion